Physician profile
Wayne Rockhill
NPI 1497188163
$5,111.41
in general payments reported to CMS, 2019-2025
17 companies · $905 in 2025
The $905 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $2,701 · 2023: $193 · 2024: $1,108 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,950.27 | 2022-2025 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $673.41 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $240.05 | 2021-2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $236.53 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.16 | 2021-2024 | Lifevest |
| Abbott Laboratories | $143.57 | 2021-2025 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $117.71 | 2025 | Amvuttra, Onpattro |
| Impulse Dynamics (USA) INC. | $95.38 | 2022-2023 | Optimizer |
| Pfizer INC. | $88.52 | 2023-2024 | |
| Edwards Lifesciences Corporation | $82.27 | 2025 | |
| Bracco Diagnostics INC. | $65.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.36 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $55.35 | 2025 | Farapulse |
| Bayer Healthcare Pharmaceuticals INC. | $45.37 | 2025 | |
| Glaxosmithkline, LLC. | $39.43 | 2025 | Nucala |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.02 | 2024 | Eliquis |
| Altathera Pharmaceuticals LLC | $29.33 | 2024-2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Rockhill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.